Nanometer antibody with effect of antagonizing porcine pseudorabies virus
By developing specific nano-antibodies, the serious threat problem of pseudorabies virus to the pig herd was solved, efficient virus identification and neutralization were achieved, effective prevention and treatment methods were provided, and the prevention and control capabilities of the pig herd were improved.
Patent Information
- Application Number
- CN202411203127.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-19
AI Technical Summary
Pseudo-rabies virus poses a serious threat to the pig herd, there are limited existing prevention and control methods, and there is a lack of diagnostic methods with high specificity and sensitivity, as well as effective antibody preparation.
A nanoantibodies were developed that contain specific heavy chain variable regions (CDR1, CDR2, CDR3) and constant region amino acid sequences, capable of highly specific identification and binding of porcine pseudorabies virus for the preparation of preventing and treating porcine pseudorabies. biological products. The nanoantibodies are expressed in host cells by recombinant expression vectors and obtained through multiple rounds of screening and purification, and have stable viral neutralization activity.
It has achieved efficient identification and neutralization of pseudorabies virus in pigs, has broad application prospects for prevention and treatment, significantly improved the prevention and control capabilities of the pig herd, and ensured its effectiveness in different environments through specificity and stability. .
Smart Images

Figure CN118978586A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of genetic engineering drugs and vaccine manufacturing, and specifically relates to a nano antibody with the efficacy of antagonizing porcine pseudorabies virus. Background Art
[0002] Pseudorabies in pigs is a serious disease caused by the Porcine Pseudorabies Virus (PRV). The virus mainly attacks pigs, especially newborn piglets. Piglets often begin to show symptoms shortly after birth, that is, on the second day, including high fever, depression, drowsiness, vomiting and diarrhea, screaming, ataxia and even running in circles, and their limbs move unconsciously after falling to the ground. Some sick pigs infected with the virus also have respiratory symptoms such as coughing, runny nose and sneezing, and a few cases show abnormalities of the central nervous system, such as body rigidity, paroxysmal spasms and hind limb motor dysfunction. The mortality rate of pseudorabies in pigs is significantly higher in piglets than in fattening pigs.
[0003] In contrast, neurological symptoms are relatively rare in fattening pigs infected with the virus, and are more often manifested as transient symptoms similar to those of a cold, and may be complicated by encephalomyelitis. Despite this, pseudorabies in pigs is an acute infectious disease, and its harm to the entire pig herd cannot be ignored. It can not only cause miscarriage in pregnant sows, and produce stillbirths or mummified fetuses, but also cause almost 100% acute mortality in newborn piglets, accompanied by significant neurological symptoms. The outbreak of pseudorabies poses a huge challenge to its prevention and control. Establishing a new highly specific and sensitive diagnostic method and obtaining antibodies with virus neutralization effects are crucial to the prevention, control and treatment of the disease.
[0004] Nanobodies are single-domain antibodies containing only the variable region of the heavy chain (VHH). Their size (volume) is about 1 / 10 of that of ordinary antibodies. They are the smallest unit known to bind to the target antigen, so they are called nanobodies. Unlike classical antibody molecules (such as IgG), nanobodies have no light chains and are composed only of the variable region of the heavy chain (VHH) and two conventional CH2 and CH3 regions. Their molecular weight is relatively small, generally around 15kDa, much smaller than the 150kDa of traditional antibodies. Nanobodies were first discovered in camel blood by Belgian scientists Hamers and others. As an animal that can survive in extreme environments (such as deserts), the camel's immune system produces this unique antibody to adapt to its special living environment. In addition, in addition to camels, nanobodies are also found in other camelids such as alpacas.
[0005] Nanobodies have a wide range of applications in many fields due to their unique advantages. Nanobodies specifically bind to cancer cells and are used for early diagnosis and imaging detection of cancer through the signal generation ability of nanoparticles. They can also be used for targeted cancer therapy to accurately deliver anticancer drugs to tumor tissues, improve the effectiveness of drugs and reduce side effects. Nanobodies can be used as key components of biosensors to detect harmful substances or biomarkers in the environment. Combined with the special properties of nanoparticles (such as fluorescence, SERS, etc.), highly sensitive and highly selective detection can be achieved. Nanobodies can be used as part of a drug delivery system to accurately deliver drugs to targeted tissues or cells. By combining the special properties of nanoparticles (such as cell membrane permeability and controlled release), the targeting, sustained release and enhanced efficacy of drugs can be achieved. Nanobodies can be used to detect pathogens of infectious diseases, such as viruses or bacteria. By combining markers such as fluorescent substances, highly sensitive pathogen detection and rapid diagnosis can be achieved. Summary of the invention
[0006] The present invention provides a nano antibody with the efficacy of antagonizing porcine pseudorabies virus. The provided nano antibody can effectively bind to porcine pseudorabies virus, has stable PRV virus neutralizing activity, and can be used to prepare biological products for the prevention and treatment of porcine pseudorabies disease.
[0007] The present invention first provides a nanobody against pseudorabies virus of pigs, wherein the nanobody comprises three complementary determining regions CDR1, CDR2 and CDR3, wherein the amino acid sequence information of CDR1, CDR2 and CDR3 is as follows:
[0008] CDR1 sequence: TTSEGSTKRRKD (SEQ ID NO: 1),
[0009] CDR2 sequence: AGPAEQSHCAR (SEQ ID NO: 2),
[0010] CDR3 sequence: AVHHRKGTDQRLA (SEQ ID NO: 3);
[0011] The nanobody provided by the present invention has a constant region comprising FR1, FR2, FR3 and FR4, and its amino acid sequence information is as follows:
[0012] FR1:QGLPGACANSGMIYLSPT(SEQ ID NO:4)、
[0013] FR2: PGECFQSADAWAG (SEQ ID NO: 5),
[0014] FR3: GRTVRLRVGDQLTSSGAS(SEQ ID NO:6),
[0015] FR4: DRLTPYMCQAGCSSANCTADGESLR (SEQ ID NO:7).
[0016] The nanobody has a specific amino acid sequence as follows: QGLPGACANSGMIYLSPTTTSEGSTKRRKDPGECFQSADAWAGAGPAEQSHCARGRTVRLR VGDQLTSSGASAVHHRKGTDQRLADRLTPYMCQAGCSSANCTADGESLR (SEQ ID NO: 8);
[0017] The present invention also provides a nucleic acid fragment encoding the above-mentioned Nanobody, a specific sequence of which is as follows:
[0018] cagggcctgccgggcgcgtgcgcgaacagcggcatgatttatctgagcccgaccaccaccagcgaaggcagcaccaaacgccgcaaagatccgggcgaatgctttcagagcgcggatgcgtgggcgggcgcgggcccggcggaacagagccattgcgcgcgcggccg caccgtgcgcctgcgcgtgggcgatcagctgaccagcagcggcgcgagcgcggtgcatcatcgcaaaggcaccgatcagcgcctggcggatcgcctgaccccgtatatgtgccaggcgggctgcagcagcgcgaactgcaccgcggatggcgaaagcctgcgc(SEQ ID NO:9).
[0019] In another aspect, the present invention also provides a recombinant expression vector, which is used to recombinantly express the above-mentioned Nanobody;
[0020] The present invention also provides a host cell containing the above recombinant expression vector.
[0021] As a specific description of the embodiment, the host cell is a competent cell DH5α.
[0022] The present invention also provides the use of the nanobody in preparing a product for preventing or treating pseudorabies virus in pigs.
[0023] The present invention provides a nano antibody capable of specifically identifying and neutralizing porcine pseudorabies virus. The screened nano antibody has highly specific recognition and binding capabilities to porcine pseudorabies virus and has application prospects in preparing preventive treatment or detection reagents for porcine pseudorabies virus. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 : SDS-PAGE electrophoresis of gE protein of PRV.
[0025] Figure 2 : Agarose gel DNA electrophoresis results of some colony PCR.
[0026] Figure 3 :Nanoantibody purification results diagram.
[0027] Figure 4 : Graph showing specificity results of nanoantibodies.
[0028] Figure 5 : Virus neutralization test results.
[0029] Figure 6 : Virus progeny titer graph after nanoantibody treatment.
[0030] Figure 7 : Gene expression level diagram after nanoantibody treatment. DETAILED DESCRIPTION
[0031] The present invention is described in detail below in conjunction with embodiments and drawings.
[0032] Example 1: Construction of PRV gE protein-specific nanobodies
[0033] 1. Preparation of gE protein antigen
[0034] Using the baculovirus expression system, the gE protein gene of the PRV virus was cloned into the bacterial plasmid pMAGIC-HIS to obtain the recombinant plasmid pMAGIC-HIS-gE. The recombinant plasmid was transferred into DH5α Escherichia coli competent cells, and the positive clone strain was screened using a selective medium plate containing karatomycin. The positive strain was inoculated into LB liquid culture medium and placed in a 37°C constant temperature shaker for shaking culture. When the bacterial growth entered the logarithmic phase, IPTG (isopropyl-β-D-thiogalactoside) was added to the culture medium to a final concentration of 0.5mmol / L. Subsequently, the culture temperature was lowered to 22°C to optimize the expression conditions of the recombinant gE protein, and the shaking culture was continued for 7 to 8 hours.
[0035] After the culture was completed, the bacterial solution was collected and centrifuged to obtain a cell precipitate. The cells were lysed by high-pressure crushing to release the intracellular components, and then centrifuged again at 12,000g to separate the supernatant from the cell debris to obtain the cell-broken supernatant containing the gE protein. The expression of the gE protein was identified by SDS-PAGE.
[0036] The broken supernatant is loaded onto an affinity chromatography column to separate the target protein, and the solution containing the purified gE protein is transferred to an ultrafiltration tube with a MWCO and centrifuged at 5,000g for 60-90min. The purified and concentrated gE protein is dissolved in 10mmol / L PBS. The protein concentration is measured by the BCA method and adjusted to a range of 1-2mg / mL. Finally, the gE protein of appropriate concentration is emulsified and used as an antigen for animal immunization experiments.
[0037] The gene sequence of the positive cloned expression strain confirmed by screening was verified by sequencing, and no mutation was found. After induction of expression, the results of electrophoresis analysis showed that ( Figure 1 ), gE protein is mainly enriched in the cytoplasm in soluble form. 2 + affinity chromatography column for purification, and after elution, desalting and concentration, the purity of the obtained gE protein exceeded 93%, and the concentration determined by the BCA method was higher than 1.3 mg / mL.
[0038] 2. Alpaca immunization and phage library construction
[0039] Healthy male alpacas of about 3 years old were used as experimental subjects, and four immunizations were performed in the cervical lymph node area (divided into left and right sides). Blood samples were collected from the jugular vein before the 2nd, 3rd, and 4th immunizations and after the 4th immunization, and the immune effect was evaluated by ELISA technology combined with goat anti-alpaca IgG-HRP complex. After completing the four immunizations, 50 mL of peripheral blood was drawn, PBMCs were separated from it, and total RNA was extracted, which was then reverse transcribed into cDNA as a template for PCR amplification. The first PCR was amplified using primers F: AGGCCTCGTTGACCGTCTCTGTA, GCGTGTATCTGGGCTCTAAT GCTR:, and a DNA fragment of about 750 bp was recovered after electrophoresis as a template for the secondary PCR. The secondary PCR was performed using primers VHH-F: TCGAGCTGGATCCATGGCTCAGTTGC, VHH-R: GGCCCCCAAGCTTAGCCATAAT, and a DNA fragment of about 400 bp was recovered. Next, the phage plasmid pComb3XSS and the secondary PCR product were treated with SpeI and SacI restriction endonucleases, respectively, and the pComb3XSS-VHH cloning vector was constructed by T4 ligase. The vector was transformed into E. coli TG1 cells by electroporation, and positive transformants were screened by ampicillin resistance. Positive strains were collected to construct a nanobody gene library, which was further amplified by infection with helper phage M13KO7 to generate a phage display library to support subsequent nanobody screening.
[0040] After four rounds of immunization with synthetic PRV gE protein, the titer of alpaca serum reached 0.94×10 5 pfu. Subsequently, lymphocytes were isolated from the peripheral blood of the immunized alpaca, and a nanobody gene library was constructed. E. coli TG1 was transformed with pComb3X-VHH vector by electroporation, and positive clones were screened on ampicillin plates, and the gene library was collected and prepared. Random PCR detection ( Figure 2 ) 150 monoclonal clones were obtained, of which 148 were positive (98.67%), and sequencing results showed that all positive sequences were unique, confirming the good diversity of the library. The nanobody phage particles were purified by phage rescue to prepare a phage display library with a titer of 10 13 pfu / mL.
[0041] 3. Nanoantibody screening and positive clone identification
[0042] The screening antigen was coated on the immunotube at a concentration of 50 μg / tube, and a BSA-coated control tube was set up. After blocking, 20 μL of phage library was added as the input phage for the first round of screening, and the mixture was rotated and incubated at room temperature for 1 hour. The immunotube was washed 20 times with PBST buffer, and after discarding the washing solution, the bound phage was eluted with trypsin solution. The elution process was terminated by adding AEBSF, and the eluate was collected as the output phage for the first round of screening. Half of the output phages were infecting E.coli TG1 for amplification. When the OD600 of the bacterial solution reached 0.5-0.55, the helper phage M13K07 was added for infection. After overnight culture, the supernatant was collected and the phage was purified by PEG / NaCl precipitation method to obtain the sub-library for the first round of screening. After the sub-library passed the titer test, it was used for the next round of screening. Another part of the output phage was taken for titer determination. Three rounds of screening were performed in a cycle, and each round used the phage sub-library amplified and purified in the previous round of screening as input. Finally, the phages obtained from the last round of screening were spread on ampicillin-resistant plates at appropriate dilutions, monoclonal colonies were selected for ELISA detection, positive clones were screened, gene sequencing was performed, and the sequencing results were translated into amino acid sequences.
[0043] After three rounds of screening, the enrichment was 64.75 times (Table 1). The clones with positive ELISA results were selected and submitted to the company for sequencing, and the sequencing results were aligned using MegAlign software.
[0044] The nucleotide sequence of one of the Nanobodies is as follows:
[0045] cagggcctgccgggcgcgtgcgcgaacagcggcatgatttatctgagcccgaccacc
[0046] accagcgaaggcagcaccaaacgccgcaaagatccgggcgaatgctttcagagcgcggatg
[0047] cgtgggcgggcgcgggcccggcggaacagagccattgcgcgcgcggccgcaccgtgcgcct
[0048] gcgcgtgggcgatcagctgaccagcagcggcgcgagcgcggtgcatcatcgcaaaggcacc
[0049] gatcagcgcctggcggatcgcctgaccccgtatatgtgccaggcgggctgcagcagcgcga
[0050] actgcaccgcggatggcgaaagcctgcgc.
[0051] The amino acid sequence of the encoded Nanobody is as follows:
[0052] QGLPGACANSGMIYLSPTTTSEGSTKRRKDPGECFQSADAWAGAGPAEQSHCARGRT VRLRVGDQLTSSGASAVHHRKGTDQRLADRLTPYMCQAGCSSANCTADGESLR.
[0053] The amino acid sequence at positions 1-18 is FR1, the amino acid sequence at positions 19-30 is CDR1, the amino acid sequence at positions 31-43 is FR2, the amino acid sequence at positions 45-54 is CDR2, the amino acid sequence at positions 55-72 is FR3, the amino acid sequence at positions 73-85 is CDR3, and the amino acid sequence at positions 86-110 is FR4.
[0054] Table 1: Enrichment rate after 3 rounds of panning
[0055] Panning times Input(cfu) Output(cfu) Output / input Enrichment rate (fold) Round 1 <![CDATA[1.8*10 13 ]]> <![CDATA[4.4*10 6 ]]> <![CDATA[2.44*10 -7 ]]> Round 2 <![CDATA[1.4*10 13 ]]> <![CDATA[8.7*10 6 ]]> <![CDATA[6.21*10 -7 ]]> 2.55 Round 3 <![CDATA[4*10 12 ]]> <![CDATA[6.3*10 7 ]]> <![CDATA[1.58*10 -5 ]]> 64.75
[0056] 4. Nanobody expression, purification and activity identification in yeast
[0057] The nanobody gene of the positive clone was synthesized and cloned into the yeast expression vector pPICZalpha A, ensuring that the myc tag and 6xHis tag sequences were retained at the 3' end. The vector was linearized using the Sac1 enzyme and then transferred into the X33 yeast strain by electroporation. Monoclonal colonies were screened on a plate containing Zeocin. The screened monoclones were routinely inoculated and induced to secrete and express nanobody proteins. During the induction process, 1% methanol was supplemented as an inducer every 24 hours, and the samples were collected after 72 hours of continuous induction. The supernatant was separated by centrifugation and the target protein was purified using a nickel affinity chromatography column.
[0058] After the purified protein sample was treated with 5 mmol PB, a concentration step was performed and then its concentration was determined. The purity and molecular weight distribution of the protein were evaluated by SDS-PAGE. For further verification, the antigen binding activity of the purified protein was detected and analyzed by immunoELISA.
[0059] The yeast vector pPICZalpha A is a secretory vector for methanol-induced expression, which can promote the secretion of nanobodies into the culture medium. To facilitate the subsequent identification and purification process, the vector is fused with a myc tag and a 6×His tag at the C-terminus of the target protein. After the expression process lasts for 72 hours, the culture supernatant is collected by centrifugation, and then the nanobodies are purified by affinity chromatography, and the uniqueness of the expression product is verified by electrophoresis. Figure 3 It can be seen that the nanobody was successfully purified and had good homogeneity. The immune reaction between the nanobody and the gE protein was identified by ELISA, and the results (Table 2) showed that the screened antibodies all had immune affinity with the antigen gE protein and had strong activity.
[0060] Table 2: Activity data of nanobodies identified by ELISA
[0061] serial number 1 2 3 gE protein 1.456 1.379 1.254 <![CDATA[1.363±0.0069 b ]]> BSA 0.132 0.128 0.087 <![CDATA[0.116±0.0004 a ]]>
[0062] Example 2: Specificity and antiviral effects of nanobodies
[0063] 1. Validation of Nanobody Specificity
[0064] The virus was coated on the ELISA plate at a concentration of 10 μg / mL, and PRV, CSFV and PEDV, which also cause diarrheal symptoms, were coated as controls and incubated overnight. Then, 1% BSA was used to block the plate, and nano antibodies were added. After incubation at 37°C for 2 hours, rabbit anti-His antibody was added after washing, and HRP-labeled anti-rabbit secondary antibody was added after further incubation and washing. The OD450 value was measured and recorded by TMB color reaction. The results are shown in Figure 4 The screened nanoantibodies showed high specificity for PRV and did not bind to other viruses.
[0065] 2. Nano-antibody neutralization experiment
[0066] Take 150 μL of nanoantibodies with an initial concentration of 1 mg / mL and dilute them 2 to 64 times with an equal amount of DMEM medium. Dilute PRV to 200TCID50 / mL, take 150 μL and mix with equal volumes of nanoantibodies of different dilutions, and incubate at 37°C for 1 hour. Replace the growth medium of PK-15 cells in a 96-well plate, add the neutralized nanoantibody-virus mixture, 3 wells per dilution, 100 μL per well, and discard the liquid after incubation at 37°C CO2 for 1 hour. Add 100 μL of DMEM maintenance solution containing 2% serum to each well and continue to culture for 72 hours. Set up negative, positive, virus and blank controls. Discard the liquid, wash with PBS, and fix the cells with 80% cold acetone for 30 minutes. Wash again with PBS, add diluted PRV monoclonal antibody and incubate for 1 hour. Discard the primary antibody, wash with PBS, and add FITC-labeled secondary antibody and incubate in the dark for 1 hour. After washing, the cells were observed under a fluorescence microscope, and PRV-infected cells were labeled with green fluorescence. The nanoantibody neutralization titer was determined as the maximum dilution that protected 50% of the cells from infection.
[0067] The results of the virus neutralization test of the nano antibody PRV-gE-Nb after multiple dilution are shown in Figure 5 At a dilution of 1:16 (corresponding to a protein concentration of 62.5 μg / mL), the nanoantibody PRV-gE-Nb protected about 50% of Vero cells and effectively resisted the cytopathic effect (CPE), confirming its significant inhibitory ability against the PRV virus and its powerful antiviral efficacy.
[0068] 3. TCID 50 Detection of viral infection by qRT-PCR
[0069] Vero cells were collected at 1×10 6 / mL density was inoculated into 96-well plates and cultured for about 24 hours. The nanoantibody (PRV-gE-Nb) was diluted to a concentration of 5, 10 or 20 μM with DMEM, and the cells were co-treated with 1000TCID50 / mL PRV. After incubation for 2 hours at 37°C and 5% CO2, the culture medium was replaced, washed three times with PBS, and fresh DMEM containing 5 μg / mL TPCK was added to continue culturing for 36 hours. The supernatant was collected to determine the virus titer, and the cells were collected for RT-qPCR analysis. The results are shown in Figure 6 and Figure 7 As shown, the viral progeny titer and gene expression level were significantly reduced after nanobody treatment.
[0070] In summary, the nanobody provided by the present invention can efficiently bind to the gE protein of the pseudorabies virus of pigs. Nanobodies have higher specificity and affinity, can remain stable in a wide range of temperature, pressure and pH, and have broad application prospects in the medical field.
Claims
1. A nanobody against pseudorabies virus, characterized in that: The nanobody comprises three complementary determining regions CDR1, CDR2 and CDR3, wherein the amino acid sequence of CDR1 is SEQ ID NO: 1, the amino acid sequence of CDR2 is SEQ ID NO: 2, and the amino acid sequence of CDR3 is SEQ ID NO:
3.
2. The Nanobody according to claim 1, characterized in that The constant region of the nanobody comprises FR1, FR2, FR3 and FR4, wherein the amino acid sequence of FR1 is SEQ ID NO:4, the amino acid sequence of FR2 is SEQ ID NO:5, the amino acid sequence of FR3 is SEQ ID NO:6, and the amino acid sequence of FR4 is SEQ ID NO:
7.
3. The Nanobody according to claim 1, characterized in that The amino acid sequence of the nanobody is SEQ ID NO:
8.
4. A nucleic acid fragment, characterized in that The nucleic acid fragment encodes the nanobody according to claim 1.
5. The nucleic acid fragment according to claim 4, wherein The sequence of the nucleic acid fragment is SEQ ID NO:
9.
6. A recombinant expression vector, characterized in that: The recombinant expression vector is used to recombinantly express the nanobody described in claim 1.
7. A host cell, characterized in that The host cell carries the recombinant expression vector according to claim 6.
8. Use of the nanobody according to claim 1 in the preparation of a product for preventing or treating pseudorabies virus in pigs.
9. A product for preventing or treating porcine pseudorabies virus, characterized in that: The preparation contains the nanobody according to claim 1 at a pharmacologically effective concentration.
